Skip to main content

Remote Job Finders (RJF)

Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs

Eli Lilly joins up with Camurus to make long-acting versions of the pharma’s obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of dosing.

M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over COVID-19 vaccine recommendations and several news outlets are questioning the validity of the White House’s Make America Healthy Again report.
Scroll to top